Clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults

Objective To evaluate the clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults.Methods 86 cases with determined diagnosis of community acquired pneumonia(mycoplasma pneumonia)of respiratory department in our hospital were chosen,in which,28 patients treated with moxifloxacin(moxifloxacin group)and 22 patients treated with cefuroxime combined with azithromycin(control group)were included in the analysis.The clinical efficacy of the 2 groups was assessed.Results No failure case was observed in both groups.Compared with control group,the moxiflocaxin group had higher defervescence rate(75.0% vs.45.5%),shorter defervescence time(3.07 d vs.5.23 d).The time from the treatment to the clinical stability(2.54 d vs.4.10 d,P0.05)and the intravenous antibiotic treatment course(8.61 d vs.11.41 d,P0.05)in moxiflocaxin group were shorter than those in control group.There was no significant difference in the total course of antibiotics use and the hospitalization time between the 2 groups.Conclusion The clinical efficacy of the 2 groups was similar,and the moxifloxacin group has shorter defervescence time,higher 72 h defervescence rate,shorter clinical stability time and shorter intravenous antibiotic course.